Combining Metabolic Modulators with Immunotherapy in Pancreatic Oncology

A New Dawn in Pancreatic Oncology

Pancreatic ductal adenocarcinoma (PDAC) continues to be one of the deadliest cancers, with a five‑year survival rate that stubbornly remains below ten percent despite advances in surgery and chemotherapy. Conventional chemotherapy regimens such as gemcitabine plus nab‑paclitaxel or FOLFIRINOX extend overall survival by only a few months and do not address the underlying immunosuppressive and metabolically hostile tumor microenvironment that fuels resistance. Recognizing these limitations, Hirschfeld Oncology has built a multidisciplinary platform that fuses precision metabolic targeting with state‑of‑the‑art immunotherapy and patient‑centered clinical care. By profiling each tumor’s glycolytic, glutaminolytic, and lipid pathways—using spatial metabolomics and genomic sequencing—the institute selects agents such as glutaminase inhibitors, glycolysis blockers, or fatty‑acid synthase antagonists to rewire cancer cell metabolism. Simultaneously, immune checkpoint blockade, cancer vaccines, or adoptive T‑cell therapies are deployed to unleash antitumor immunity once the metabolic barriers are softened. This integrated, multimodal approach not only aims to improve response rates and overall survival but also personalizes treatment to the individual’s tumor biology and life circumstances, heralding a new dawn in pancreatic oncology. Ongoing clinical trials at Hirschfeld are testing these combinations, and early signals suggest enhanced durability of responses across patient cohorts.

Barriers to Immunotherapy in PDAC

Why immune checkpoint blockade is largely ineffective in pancreatic cancer? Pancreatic ductal adenocarcinoma (PDAC) is intrinsically non‑immunogenic: it harbors a low tumor mutational burden and few neo‑antigens, resulting in weak priming of cytotoxic T cells. The dense, desmoplastic stroma—composed of cancer‑associated fibroblasts, abundant extracellular‑matrix proteins, and hyaluronic acid—creates a physical barrier that limits immune‑cell infiltration and impedes drug delivery. Within this hostile microenvironment, immunosuppressive cell populations dominate, including regulatory T cells, myeloid‑derived suppressor cells, and M2‑polarized tumor-associated macrophages, all of which secrete TGF‑β, IL‑10, and other cytokines that dampen CD8⁺ T‑cell activity. Metabolic competition further exhausts effector T cells: tumor cells consume glucose voraciously, depleting glucose for T cells, while lactate accumulation and kynurenine production from IDO/TDO pathways suppress T‑cell function and promote regulatory phenotypes. Low expression of checkpoint ligands such as PD‑L1 and minimal baseline CD8⁺ infiltration mean that anti‑PD‑1 blockade have few targets to act upon. Consequently, single‑agent checkpoint inhibition yields response rates below 5 % in PDAC, driving the pursuit of combination strategies that remodel the stroma, re‑program tumor metabolism, and restore T‑cell fitness.

Metabolic Targets: PIKfyve and Beyond

PIKfyve, a phosphatidylinositol‑3‑phosphate 5‑kinase, controls endolysosomal trafficking and autophagy. PDAC relies on these pathways for survival in nutrient‑poor settings. Genetic or pharmacologic inhibition disrupts lysosomal function, blocks autophagic degradation, and forces de novo lipid synthesis, creating a vulnerability. In mouse models and human PDAC cells, loss of PIKfyve slows growth, and combined with KRAS‑MAPK blockade it induces synthetic lethality and apoptosis.

PDAC’s metabolic phenotype combines aerobic glycolysis (Warburg) with glutamine‑driven anaplerosis and altered lipid synthesis. Subtype analysis identifies four glucose‑dependent (Warburg, reverse‑Warburg, mixed, null) and four glutamine‑dependent (canonical, non‑canonical, mixed, null) groups, each correlating with outcomes. The Warburg subtype shows GLUT1, nerve infiltration, advanced stage and poorer survival, whereas high BNIP3 (an autophagy marker) predicts longer survival. Non‑canonical glutamine metabolism, driven by GOT1 and GLUD1, fuels biosynthesis and redox balance in hypoxic, nutrient‑depleted tumors.

Metabolic therapies under investigation include glutaminase inhibitors (telaglenastat, CB‑839), glycolysis blockers (2‑deoxy‑D‑glucose, LDHA inhibitors), and lipid‑targeting agents (FASN inhibitors, avasimibe). Mitochondrial inhibitors, autophagy blockers, and amino‑acid depleters further stress tumor metabolism. Combining these agents with checkpoint inhibitors or radiotherapy yields synergistic anti‑tumor effects in pre‑clinical models and early trials, supporting a multi‑modal strategy to overcome PDAC’s immunosuppressive TME.

Patient Stories and Historical Cases

Steve Jobs' alternative treatment journey

Steve Jobs was diagnosed in 2003 with a pancreatic neuroendocrine tumor, a rare subtype of pancreatic cancer. Rather than undergoing immediate conventional therapy, he pursued a complementary‑and‑alternative medical (CAM) regimen for about nine months. His approach combined acupuncture, a variety of botanical and herbal supplements, and strict dietary changes aimed at “detoxifying” his body. Scientific evidence does not support these modalities as effective against pancreatic malignancies. As the tumor grew, Jobs ultimately elected for standard surgical resection followed by conventional chemotherapy, but the delay may have impacted disease progression.

Emotional burden of pancreatic cancer

Depression is the emotion most frequently linked to pancreatic cancer. Studies consistently show a markedly higher prevalence of depressive symptoms among patients, often accompanied by anxiety. The psychological toll is amplified by the disease’s aggressive nature, limited therapeutic options, and rapid health decline. In many cases, depressive mood appears even before a formal diagnosis, suggesting a possible biological connection between tumor biology and mood regulation. Addressing mental health—through counseling, psychiatric care, and supportive services—is therefore a critical component of comprehensive pancreatic‑cancer management.

Current Landscape of Immunotherapy Approval and Success

Pancreatic ductal adenocarcinoma (PDAC) has virtually no approved immunotherapy for the general patient population. The only checkpoint inhibitor with an FDA indication is pembrolizumab (Keytruda), which is authorized for tumors that are microsatellite‑instability‑high (MSI‑H) or mismatch‑repair‑deficient (dMMR) – roughly <2 % of pancreatic cancers. All other agents, such as nivolumab, atezolizumab, or CTLA‑4 antibodies, have not received approval for PDAC and are used only within clinical trials or off‑label.

Response rates with immune‑checkpoint monotherapy in unselected PDAC are modest, typically 2‑5 %. In the MSI‑H/dMMR subgroup, efficacy rises sharply; early studies report objective response rates exceeding 20 %, and a recent case series of 14 exceptional responders (42 % MSI‑H) showed an 82 % partial‑response rate, median progression‑free survival of ~12 months, and 1‑year survival around 80 %. Combination regimens that pair immunotherapy with chemotherapy, radiation, or metabolic modulators are under active investigation and have demonstrated modest improvements in objective response (≈5‑12 %) and safety. Nevertheless, for the vast majority of PDAC patients, standard chemotherapy, targeted therapy, or trial enrollment remain the primary treatment options.

Phase I/II trials of pembrolizumab with gemcitabine/nab‑paclitaxel or metabolic agents (metformin, glutaminase inhibitors) report disease‑control 30‑45 % and suggest biomarker‑driven selection could broaden immunotherapy benefit in PDAC.

Emerging Combination Strategies

Triple‑combination therapy for pancreatic cancer
Triple‑combination therapy pairs a KRAS‑G12C inhibitor (RMC‑6236/daraxonrasib) with the irreversible EGFR/HER2 kinase inhibitor afatinib and the selective STAT3 PROTAC degrader SD36. By simultaneously blocking upstream EGFR, downstream RAF1, and orthogonal STAT3, pre‑clinical mouse models and patient‑derived xenografts showed complete tumor regression with no resistance for >200 days and acceptable tolerability, offering a biology‑driven approach to overcome KRAS‑driven resistance.

Can immunotherapy and targeted therapy be given together?
Yes. Targeted agents remodel the pancreatic tumor microenvironment—reducing immunosuppressive cells, lowering lactate, and enhancing antigen presentation—thereby potentiating checkpoint blockade. Early‑phase trials in solid tumors, including PDAC, report synergistic activity, though combined toxicities require careful dosing and monitoring.

What new immunotherapies are being investigated for pancreatic cancer?
Bispecific antibodies linking tumor antigens to CD3, STING agonists, on‑ytic viruses, next‑generation CAR‑T cells engineered to resist the desmoplastic stroma, personalized KRAS‑mutant vaccines, and adoptive tumor‑infiltrating lymphocyte transfer are under active investigation. These modalities aim to convert the immunologically “cold” PDAC into a responsive, inflamed tumor.

Is immunotherapy effective for stage 4 pancreatic cancer?
As a monotherapy, checkpoint inhibitors yield low response rates in stage 4 PDAC. Combination regimens with chemotherapy, targeted agents, or vaccines show early disease‑control signals but remain investigational; larger trials are needed before standard adoption.

Stage 4 Pancreatic Cancer Treatment Options

What new treatments are available for stage 4 pancreatic cancer?

Recent advances expand options beyond standard gemcitabine‑based regimens. Modified FOLFIRINOX remains a backbone, and for patients with BRCA1/2 or other homologous‑recombination defects maintenance PARP inhibition (olaparib, rucaparib) improves progression‑free survival. Targeted agents now address specific drivers: KRAS G12C inhibitors (sotorasib, adagrasib) for the subset harboring that mutation, and TRK inhibitors (larotrectinib, entrectinib) for rare NTRK fusions. Immunotherapy is gaining traction in biomarker‑selected disease—microsatellite‑instable or high‑tumor‑mutational‑burden tumors receive pembrolizumab, while peptide‑based vaccines, mRNA neoantigen platforms, and adoptive cell therapies (CAR‑T, TCR‑engineered T cells) are being tested. Stromal‑modulating approaches such as hyaluronidase (PEGPH2000063-7)), focal‑adhesion‑kinase inhibitors, and oncolytic viruses are also combined with chemotherapy to improve drug delivery and immune infiltration.

What are common side effects of immunotherapy for pancreatic cancer?

Immune‑checkpoint blockade can provoke immune‑related adverse events that mirror those seen in melanoma or lung cancer. The most frequent toxicities are skin rash, pruritus and vitiligo‑like changes. Gastro‑intestinal inflammation (colitis) and hepatic injury (hepatitis) occur in 10‑20 % of patients, while pneumonitis, endocrinopathies (thyroiditis, adrenal insufficiency) and arthritis are less common but may be severe. Fatigue, nausea and low‑grade diarrhea are also reported. Early recognition is critical; management usually involves corticosteroids, temporary treatment interruption, and, for refractory cases, additional immunosuppressants such as infliximab.

Metabolic Modulation Approaches

Pancreatic ductal adenocarcinoma (PDAC) adopts a hybrid metabolic phenotype: intense aerobic glycolysis (Warburg effect) coupled with glutamine‑driven anaplerosis, lipid biosynthesis, and extensive autophagy. This rewiring fuels rapid growth, creates a nutrient‑deprived, hypoxic microenvironment, and drives immunosuppression.

Targeting glycolysis, glutaminolysis, and lipid synthesis – Clinical programs test glycolytic inhibitors (2‑deoxy‑D‑glucose, HK2 blockers, LDHA inhibitors such as NHI‑Glc‑2 to blunt lactate production and restore glucose for CD8⁺ T cells. Glutaminase inhibitors (telaglenastat/CB‑839, CB‑839) block GLS1, reducing α‑ketoglutarate generation and limiting NADPH production. Lipid metabolism is attacked with fatty‑acid synthase inhibitors (orlistat, TVB‑2640) and cholesterol‑targeting agents (statins, ACAT‑1 inhibitor avasimibe) that disrupt membrane raft formation and signaling.

Metabolic enzymes and their inhibitors in PDAC – Key enzymes include GLUT1, HK2, PKM2, LDHA (glycolysis); GLS1, GOT1 (glutaminolysis); FASN, ACLY (lipogenesis); and MCT transporters (lactate shuttling). Inhibitors such as 7ACC2 (MCT1), 2‑DG (HK2), and ACAT1 blockers have shown pre‑clinical synergy with immune‑checkpoint blockade, enhancing cytotoxic T‑cell infiltration and reducing regulatory T‑cell recruitment.

What metabolic therapies are being explored for pancreatic cancer? – Strategies focus on disrupting altered fuel pathways (glycolysis, glutaminolysis, lipid synthesis, impairing mitochondrial oxidative phosphorylation, depleting essential amino acids, and inhibiting autophagy. Many agents are now paired with PD‑1/PD‑L1 antibodies or vaccines to remodel the tumor microenvironment and overcome immune resistance.

What is the metabolic phenotype of pancreatic cancer? – PDAC displays a Warburg‑type high glycolytic flux, a non‑canonical glutamine utilization pathway (GOT1‑dependent), and up‑regulated lipid synthesis, all of which support survival in a hypoxic, nutrient‑poor niche and contribute to therapeutic resistance.

Innovations in Device Therapy and Clinical Trials

Optune Pax® delivers low‑intensity, alternating electric fields via adhesive patches that selectively disrupt rapid cancer‑cell mitosis without harming normal tissue. Integration of TTFields with chemotherapy has already shown synergistic tumor‑cell killing, and ongoing investigations are expanding the combination to include immune‑checkpoint inhibitors. Early‑phase studies pairing Optune Pax® with PD‑1 blockade (e.g., pembrolizumab) report enhanced CD8⁺ T‑cell infiltration and modest improvements in disease‑control rates, suggesting that the electromagnetic‑induced immunogenic cell death may prime the tumor microenvironment for immunotherapy.

Future trials aim to refine sequencing, dosing, and biomarker‑guided patient selection to maximize the triple‑combination potential of TTFields, chemotherapy, and immunotherapy, potentially establishing a new standard of care for locally advanced pancreatic cancer.

Global Care and Future Outlook

Access to optimal pancreatic‑cancer care varies worldwide. The United States offers the most comprehensive ecosystem: a dense network of NCI‑designated comprehensive cancer centers that combine surgery, chemotherapy, radiation, and a large portfolio of active clinical trials, all coordinated by multidisciplinary teams. Germany follows closely, with specialized pancreatic units, strong translational research, and broad trial access; Japan and South Korea also provide excellent surgical expertise and innovative systemic options, but the breadth of trial availability and coordinated care in the U.S. makes it the leading destination for patients seeking the best outcomes.

Therapies expected in 2025 include KRAS G12D inhibitors such as adagrasib, STING agonists that prime innate immunity, and neoantigen vaccines combined with checkpoint blockade and metabolic modulators (e.g., glutaminase or glycolysis inhibitors). FDA breakthrough designation for metabolic‑immunotherapy combos and approval of tumor‑treating fields for locally advanced disease illustrate momentum toward multi‑modal regimens.

The “obesity paradox” in cancer immunotherapy describes the observation that overweight patients often experience superior survival on immune‑checkpoint inhibitors. Proposed mechanisms involve leptin‑driven up‑regulation of PD‑1 and other checkpoints, which may render tumor‑infiltrating lymphocytes more responsive to blockade, as well as altered tumor metabolism that reduces immunosuppressive lactate.

A Blueprint for the Future

Pancreatic ductal adenocarcinoma (PDAC) remains a therapeutic nightmare, but emerging data suggest that a three‑pronged strategy—metabolic modulation, immune activation, and precision medicine—can finally breach its defenses. Low‑dose radiotherapy or tumor‑treating fields can expose neo‑antigens, while checkpoint blockade (PD‑1/PD‑L1) awakens exhausted T cells. Simultaneously, agents that blunt glycolysis (2‑DG), glutaminolysis (CB‑839), or lactate export (MCT inhibitors) restore nutrient balance, reduce lactate‑driven immunosuppression, and re‑program tumor‑associated fibroblasts. Multi‑omics and spatial profiling identify each patient’s dominant metabolic vulnerability, allowing clinicians to pair the right metabolic inhibitor with immunotherapy and, when appropriate, targeted KRAS or DNA‑repair agents. Hirschfeld Oncology has built a multidisciplinary platform that integrates these insights into standard practice. Its clinical trial network evaluates combos such as pembrolizumab + SBRT + trametinib or CPI‑613 + PD‑1 blockade, while its precision‑medicine team uses tumor sequencing, metabolomic signatures, and organoid testing to tailor therapy. By coupling cutting‑edge metabolic drugs with immune‑engaging regimens, Hirschfeld Oncology delivers personalized, biologically rational treatment plans that aim to convert cold PDAC tumors into responsive, long‑lasting disease control. Future trials will explore dosing schedules that synchronize metabolic stress with immune activation, and will incorporate monitoring to adjust patient therapy on the fly, ensuring efficacy and minimizing toxicity.